Hormone therapy for prostate cancer: A topical perspective

Urology

Volumn 47, Issue 1 SUPPL. 1, 1996, Pages 3-12

  Klein, Eric A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; FINASTERIDE; FLUTAMIDE; GESTAGEN; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CARDIOTOXICITY; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GYNECOMASTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; PRECANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY;

AGED; ANDROGEN ANTAGONISTS; CLINICAL TRIALS; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 0029584319     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(96)80002-1     Document Type: Article

References (25)

1. Huggins C, and Hodges CV: Studies on prostatic cancer. I. The effect of castration of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
2. Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011-1017, 1967.
3. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas ATA, Comaru-Schally AM, and Schally AU: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 79:1658-1662, 1982.
4. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281-1286, 1984.
5. Winfield H, and Trachtenberg J: A comparison of a powerful luteinizing hormone-releasing hormone analogue agonist and estrogen in the treatment of advanced prostate cancer. J Urol 131:1107-1109, 1984.
6. Trachtenberg J: The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol 129:1149-1152, 1983.
7. Pavone-Macaluso M, Pavone C, Serretta V, and Daricello G: Antiandrogens alone or in combination for treatment of prostate cancer: the European experience. Urology 34 (suppl):27-36, 1989.
8. Kennealey GT, and Furr BJ: Use of the nonsteroid anti-androgen Casodex in advanced prostatic carcinoma. Urol Clin North Am 18:99-110, 1991.
9. Sogani PC, Vagaiwala MR, and Whitmore WF Jr: Experience with flutamide in patients with advanced prostate cancer without prior endocrine therapy. Cancer 54:744-750, 1984.
10. Labrie F, Dupont A, Belanger A, Emond J, and Monfette G: Simultaneous administration of pure antiandrogens, a combination necessary for die use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 81:3861-3863, 1984.
11. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989.
12. Tyrrell CJ, Altwein JE, Klippel F, Varenhorst E, Lunglmayr G, Boccardo F, Holdaway IM, Haefliger JM, and Jordaan JP: A multicenter randomized trial comparing die luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group. J Urol 146:1321-1326, 1991.
13. The Canadian Anandron Study Group: Total androgen ablation in the treatment of metastatic prostatic cancer. Semin Urol 8:159-165, 1990.
14. Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, and Bergeron V: Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Steroid Biochem 23:833-841, 1985.
15. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al.: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 149:77-82, 1993.
16. Scher HI, and Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1994.
17. Small EJ, and Carroll PR: Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410, 1994.
18. Dawson NA, and McLeod DG: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946-1947, 1995.
19. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, and Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45:839-844, 1995.
20. Whitmore WF Jr: Proceedings: the natural history of prostate cancer. Cancer 32:1104-1112, 1973.
21. Brawley OW, and Thompson IM: Chemoprevention of prostate cancer. Urology 43: 594-599, 1994.
22. Brawer MK: Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol 23:242-248, 1993.
23. Bostwick DG: Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem 10 (suppl):16H-19H, 1992.
24. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy: the Johns Hopkins experience after 10 years. Urol Clin North Am 20:713-725, 1993.
25. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP, and Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. J Urol 154:424, 1995.